NASDAQ:EIDX Eidos Therapeutics (EIDX) Stock Price, News & Analysis → The attacks will come for me after releasing this… (From Porter & Company) (Ad) Free EIDX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$122.21▼$122.2150-Day Range$120.98▼$128.5152-Week Range$28.39▼$132.54VolumeN/AAverage Volume128,113 shsMarket Capitalization$4.75 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Eidos Therapeutics alerts: Email Address Ad Porter & CompanyThe attacks will come for me after releasing this…America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that, if successful, could be more financially and culturally devastating than the dot-com blowup of 2000, the 2008 financial crisis, or the COVID crash.Click here to see how you can protect yourself today. About Eidos Therapeutics Stock (NASDAQ:EIDX)Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.Read More Ad Porter & CompanyThe attacks will come for me after releasing this…America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that, if successful, could be more financially and culturally devastating than the dot-com blowup of 2000, the 2008 financial crisis, or the COVID crash.Click here to see how you can protect yourself today. EIDX Stock News HeadlinesMay 7, 2024 | msn.comStellar Blade: How To Drain Water In Eidos 7 (Oblivion Side Quest)April 26, 2024 | msn.comStellar Blade: How to Solve Monorail Puzzle on Eidos 7February 3, 2024 | thestreet.comThe Anglo File: Game Over for Board Lapses at EidosJanuary 31, 2024 | msn.comDeus Ex game canceled as nearly 100 Eidos-Montreal staff laid offJanuary 31, 2024 | msn.comEmbracer Group reportedly cancels unannounced Deus Ex game, lays off staff at Eidos MontrealJanuary 31, 2024 | msn.comEmbracer lays off 97 Eidos employees and cancels new Deus Ex gameJuly 16, 2023 | investing.comEidos Therapeutics Inc (EIDX)June 27, 2023 | finance.yahoo.comVTGN - Vistagen Therapeutics, Inc.April 7, 2023 | msn.comEidos' Guardians of the Galaxy Can Still Ride the Wave of Volume 3's May ReleaseFebruary 24, 2023 | benzinga.comCara Therapeutics Stock (NASDAQ:CARA), Quotes and News SummaryDecember 28, 2022 | finanznachrichten.deAdvanced Proteome Therapeutics Corp.: Advanced Proteome Therapeutics Announces Closing of Non-Brokered Private PlacementJuly 28, 2022 | msn.comSony Eyeing Square Enix Tokyo Purchase Months After Crystal Dynamics, Eidos Montreal SaleJuly 26, 2022 | msn.comSony wants to buy Square Enix Tokyo claims Eidos-Montréal founderMay 2, 2022 | msn.comThe Eidos games that could be revived with the Embracer acquisitionMay 2, 2022 | venturebeat.comEmbracer agrees to buy Crystal Dynamics, Eidos-Montréal, Square Enix Montréal, and their IPOctober 8, 2021 | msn.comVideo-game studio Eidos-Montreal is switching to a 4-day work week for its staff, cutting weekly hours from 40 to 32 while keeping salaries the sameSeptember 22, 2021 | news.yahoo.comEidos-Montréal gambles with entry into "Guardians of the Galaxy" franchiseJuly 24, 2021 | nasdaq.comEidos Therapeutics, Inc. Common Stock (EIDX)See More Headlines Receive EIDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eidos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/29/2020Today6/15/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:EIDX CUSIPN/A CIKN/A Webwww.eidostx.com Phone415-887-1471FaxN/AEmployees70Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,830,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-65.21% Return on Assets-53.04% Debt Debt-to-Equity Ratio0.14 Current Ratio11.10 Quick Ratio11.10 Sales & Book Value Annual Sales$26.69 million Price / Sales177.99 Cash FlowN/A Price / Cash FlowN/A Book Value$4.57 per share Price / Book26.74Miscellaneous Outstanding Shares38,873,000Free FloatN/AMarket Cap$4.75 billion OptionableNot Optionable Beta-0.16 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Neil Kumar (Age 42)CEO & Director Comp: $247.68kDr. Uma Sinha (Age 64)Chief Scientific Officer & Director Comp: $533.4kDr. Cameron Turtle DPHIL (Age 31)Ph.D., Chief Bus. Officer Comp: $578.4kDr. Jonathan C. Fox FACC (Age 64)M.D., Ph.D., Pres & Chief Medical Officer Dr. Isabella Graef M.D. (Age 56)Co-Founder & Board Advisor Dr. Mamoun Alhamadsheh Ph.D.Pharm.D., Co-FounderMr. Franco Valle (Age 40)Sr. VP of Fin., Principal Accounting Officer & Sec. Mr. Matt OuttenChief Commercial OfficerDr. Hoyoung Huh (Age 52)Consultant More ExecutivesKey CompetitorsAgios PharmaceuticalsNASDAQ:AGIOIntellia TherapeuticsNASDAQ:NTLAProthenaNASDAQ:PRTAArcturus TherapeuticsNASDAQ:ARCTALX OncologyNASDAQ:ALXOView All Competitors EIDX Stock Analysis - Frequently Asked Questions How were Eidos Therapeutics' earnings last quarter? Eidos Therapeutics, Inc. (NASDAQ:EIDX) announced its quarterly earnings results on Thursday, October, 29th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by $0.08. The business earned $0.13 million during the quarter. What other stocks do shareholders of Eidos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eidos Therapeutics investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Aduro Biotech (ADRO), Micron Technology (MU), Pfizer (PFE), Verastem (VSTM), ImmunoGen (imgn), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY) and Axsome Therapeutics (AXSM). When did Eidos Therapeutics IPO? Eidos Therapeutics (EIDX) raised $101 million in an initial public offering (IPO) on Wednesday, June 20th 2018. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Barclays was co-manager. This page (NASDAQ:EIDX) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eidos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eidos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.